Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights
IND filing for IMM-1-104, which has displayed broad preclinical pan-KRAS/NRAS activity, expected this quarter; Enrollment of first patient in planned Phase 1/2a clinical trial expected in Q4 2022
IND filing for IMM-6-415, designed to sensitize resistant tumors to select immunotherapies, expected in 2023
Cash, cash equivalents and marketable securities of $128.1M is expected to provide cash runway into Q3 2024
CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, today reported financial results for the second quarter ended June 30, 2022 and provided recent business highlights.
“We believe IMM-1-104 has great potential to benefit the many cancer patients with tumors driven by KRAS or NRAS mutations,” said Ben Zeskind, Ph.D., MBA, chief executive officer of Immuneering Corporation. “We are thrilled to be gearing up to file our IND for IMM-1-104, which remains on track to be filed this quarter, and we expect to enroll the first patient in our planned Phase 1 clinical trial in the fourth quarter of 2022. To date, we have generated strong preclinical results across a broad range of animal tumor models including KRAS-G12C, KRAS-G12D, KRAS-G12S, KRAS-G12V, NRAS-Q61R, and BRAF-V600E mutations. This compelling preclinical data package demonstrates IMM-1-104’s potential as a third generation MEK inhibitor to have broad activity that is independent of the specific mutation activating the MAPK pathway.”
Corporate Highlights
- IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V Mutant Pancreatic Cancer: In May 2022, Immuneering reported preclinical data at the ASCO 2022 meeting titled “Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or adagrasib in KRAS mutant pancreatic tumors” in an online publication. In the Capan-2 PDAC KRAS-G12V xenograft animal model, all doses and schedules of IMM-1-104 (75, 100, 150mg/kg BID p.o. or 150mg/kg QD p.o.) showed tumor growth inhibition (TGI) of 49-84% after 21 days of treatment. Taken together with IMM-1-104’s demonstrated preclinical activity across KRAS-G12C, KRAS-G12D, KRAS-G12S, NRAS-Q61R and BRAF-V600E, this new data in KRAS-G12V shows the potential to offer a unique advantage in pancreatic cancer where a broad range of KRAS mutations occur.
- IMM-1-104 translational modeling shows models sensitive to IMM-1-104 were enriched for MAPK Driver Mutations: In May 2022, Immuneering reported a second preclinical abstract at the ASCO 2022 meeting entitled “Translational modeling for patients with RAS mutant tumors: Profiling the dual-MEK inhibitor IMM-1-104 in a humanized 3D assay” in an online publication. IMM-1-104’s pharmacological activity was profiled across 52 human tumor cell lines spanning a variety of mutations in a 3D tumor growth assay (3D-TGA). KRAS mutant pancreatic cancer and NRAS mutant melanoma demonstrated broad sensitivity followed closely by KRAS mutant NSCLC and KRAS mutant CRC to IMM-1-104 in the 3D-TGA, and thus are included in Immuneering’s expected Phase 1/2a clinical trials.
Key Development Highlights
- IMM-1-104 IND submission expected this quarter: Immuneering remains on track to file its IND for IMM-1-104 this quarter.
- IMM-1-104 first patient enrolled expected in Q4 2022: Immuneering expects to enroll the first patient in its Phase 1/2a clinical trial evaluating IMM-1-104 in advanced solid tumors in patients with tumors driven by RAS mutations in the fourth quarter of 2022.
- Second IND submission for IMM-6-415 expected in 2023: IMM-6-415, the company’s MEK-io program, is currently in IND-enabling studies. Immuneering expects to file an IND application for IMM-6-415 in 2023. IMM-6-415 is a dual-MEK inhibitor that has drug-like properties optimized for immune normalization and may enhance and/or expand clinical responses to checkpoint inhibitors.
Second Quarter 2022 Financial Highlights
- Cash Position: Cash and cash equivalents and marketable securities as of June 30, 2022 were $128.1 million, compared with $150.2 million as of December 31, 2021.
- Research and Development (R&D) Expenses: R&D expenses for the second quarter ended June 30, 2022 were $8.0 million, compared with $7.0 million for the same period in 2021. The increase in R&D expenses was primarily attributable to higher preclinical costs related to the company’s lead programs and increased personnel to support ongoing research and development activities.
- General and Administrative (G&A) Expenses: G&A expenses for the second quarter ended June 30, 2022 were $3.7 million, compared with $1.3 million for the same period of 2021. The increase in G&A expenses was primarily attributable to an increase in headcount to support the company’s business and to costs related to operating as a public company.
- Net Loss: Net loss attributable to common stockholders was $11.5 million, or $0.44 per share, for the second quarter ended June 30, 2022, compared to $8.0 million, or $1.61 per share, for the second quarter ended June 30, 2021.
2022 Financial Guidance
- Immuneering reiterates full year GAAP operating expenses to be between $55.0 million and $60.0 million including estimated non-cash stock-based compensation. Based on cash, cash equivalents and marketable securities as of June 30, 2022, and current operating plans, the company expects its cash runway to extend into the third quarter of 2024.
About Immuneering Corporation
Immuneering aims to improve patient outcomes by advancing a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, developed using its translational bioinformatics platform. Immuneering has more than a decade of experience applying translational bioinformatics to generate insights into drug mechanism of action and patient treatment response. Building on this experience, Immuneering's disease-agnostic discovery platform enables the company to create product candidates based on 1) biological insights that are both counterintuitive and deeply rooted in data, and 2) novel chemistry. Immuneering's lead product candidate, IMM-1-104, aims to achieve pan-KRAS/NRAS activity that selectively impacts cancer cells to a greater extent than healthy cells. IMM-1-104 is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR to modulate the signaling dynamics of the MAPK pathway by driving deep cyclic inhibition that deprives tumor cells of the sustained proliferative signaling required for rapid growth, while providing a cadenced, moderate level of signaling sufficient to spare healthy cells. IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided by Immuneering's proprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics. In addition to IMM-1-104, Immuneering is evaluating its MEK-io product candidate, IMM-6-415, in IND-enabling studies, and has five other oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway, as well as two discovery stage neuroscience programs.
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," including, without limitation, statements regarding Immuneering’s expectations regarding the sufficiency of Immuneering’s cash, cash equivalents and marketable securities, its full year GAAP operating expenses for 2022, the treatment potential of IMM-1-104 and IMM-6-415, the timing of submission of the IND and commencement of clinical trials for IMM-1-104 and IMM-6-415, and Immuneering’s ability to advance its pipeline and further diversify its portfolio and make progress towards its longstanding goal of creating better medicines for cancer patients. Forward-looking statements are based on Immuneering’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology and neuroscience drug development, including target discovery, target validation, lead compound identification, lead compound optimization, preclinical studies and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Immuneering’s most recent Form 10-Q filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Immuneering
Corporate Contact:
Rebecca Kusko, Ph.D.
Immuneering Corporation
rkusko@immuneering.com
617-500-8080
Investor Contact:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
917-513-5303
IMMUNEERING CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | $ | 94,419 | $ | 660,040 | $ | 278,117 | $ | 1,408,240 | ||||||||
| Cost of revenue | 47,933 | 318,601 | 138,778 | 727,763 | ||||||||||||
| Gross profit | 46,486 | 341,439 | 139,339 | 680,477 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 7,981,075 | 6,991,965 | 17,031,517 | 12,382,985 | ||||||||||||
| General and administrative | 3,704,143 | 1,340,398 | 7,664,112 | 2,524,422 | ||||||||||||
| Amortization of intangible asset | 7,317 | — | 15,420 | — | ||||||||||||
| Total operating expenses | 11,692,535 | 8,332,363 | 24,711,049 | 14,907,407 | ||||||||||||
| Loss from operations | (11,646,049 | ) | (7,990,924 | ) | (24,571,710 | ) | (14,226,930 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 142,799 | 3,259 | 275,304 | 9,614 | ||||||||||||
| Other expense | (24,053 | ) | — | (127,271 | ) | - | ||||||||||
| Net loss | $ | (11,527,303 | ) | $ | (7,987,665 | ) | $ | (24,423,677 | ) | $ | (14,217,316 | ) | ||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.44 | ) | $ | (1.61 | ) | $ | (0.93 | ) | $ | (2.87 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 26,386,343 | 4,954,553 | 26,372,787 | 4,952,352 | ||||||||||||
| Other comprehensive loss: | ||||||||||||||||
| Unrealized losses from marketable securities | (14,166 | ) | — | (132,552 | ) | — | ||||||||||
| Comprehensive Loss | $ | (11,541,469 | ) | $ | (7,987,665 | ) | $ | (24,556,229 | ) | $ | (14,217,316 | ) | ||||
IMMUNEERING CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| June 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 87,937,479 | $ | 74,888,145 | ||||
| Marketable securities, current | 40,163,875 | 74,311,203 | ||||||
| Accounts receivable | 178,425 | 246,040 | ||||||
| Prepaids and other current assets | 890,409 | 2,888,608 | ||||||
| Total current assets | 129,170,188 | 152,333,996 | ||||||
| Marketable securities, non-current | — | 996,560 | ||||||
| Property and equipment, net | 985,007 | 807,223 | ||||||
| Goodwill | 6,690,431 | 6,701,726 | ||||||
| Intangible asset | 423,580 | 439,000 | ||||||
| Right-of-use assets, net | 4,691,157 | 5,324,198 | ||||||
| Other assets | 89,579 | 102,129 | ||||||
| Total assets | $ | 142,049,942 | $ | 166,704,832 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,240,241 | $ | 1,394,340 | ||||
| Accrued expenses | 2,226,687 | 3,965,447 | ||||||
| Other liabilities, current | 47,213 | — | ||||||
| Lease liabilities, current | 286,374 | 274,039 | ||||||
| Total current liabilities | 3,800,515 | 5,633,826 | ||||||
| Long-term liabilities: | ||||||||
| Other liabilities, non-current | 9,898 | — | ||||||
| Lease liabilities, non-current | 4,644,683 | 5,090,897 | ||||||
| Total liabilities | 8,455,096 | 10,724,723 | ||||||
| Commitments and contingencies (Note 12) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively; 0 shares issued or outstanding at June 30, 2022 and December 31, 2021 | — | — | ||||||
| Class A common stock, $0.001 par value, 200,000,000 shares authorized at June 30, 2022 and December 31, 2021; 26,392,299 and 26,320,199 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 26,392 | 26,320 | ||||||
| Class B common stock, $0.001 par value, 20,000,000 shares authorized at June 30, 2022 and December 31, 2021; 0 shares issued and outstanding at June 30, 2022 and December 31, 2021 | — | — | ||||||
| Additional paid-in capital | 217,447,080 | 215,276,186 | ||||||
| Accumulated other comprehensive loss | (181,561 | ) | (49,009 | ) | ||||
| Accumulated deficit | (83,697,065 | ) | (59,273,388 | ) | ||||
| Total stockholders' equity | 133,594,846 | 155,980,109 | ||||||
| Total liabilities and stockholders' equity | $ | 142,049,942 | $ | 166,704,832 | ||||
